158 related articles for article (PubMed ID: 7671107)
21. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
22. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
23. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1.
Balzarini J; De Clercq E; Baumgartner H; Bodenteich M; Griengl H
Mol Pharmacol; 1990 Mar; 37(3):395-401. PubMed ID: 2156153
[TBL] [Abstract][Full Text] [Related]
24. Pronounced cytostatic activity and bystander effect of a novel series of fluorescent tricyclic acyclovir and ganciclovir derivatives in herpes simplex virus thymidine kinase gene-transduced tumor cell lines.
Balzarini J; Ostrowski T; Goslinski T; De Clercq E; Golankiewicz B
Gene Ther; 2002 Sep; 9(17):1173-82. PubMed ID: 12170381
[TBL] [Abstract][Full Text] [Related]
25. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET.
Tseng JC; Zanzonico PB; Levin B; Finn R; Larson SM; Meruelo D
J Nucl Med; 2006 Jul; 47(7):1136-43. PubMed ID: 16818948
[TBL] [Abstract][Full Text] [Related]
26. 5-Iodo-2'-deoxy-L-uridine and (E)-5-(2-bromovinyl)-2'-deoxy-L-uridine: selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity, and cytotoxicity studies.
Spadari S; Ciarrocchi G; Focher F; Verri A; Maga G; Arcamone F; Iafrate E; Manzini S; Garbesi A; Tondelli L
Mol Pharmacol; 1995 Jun; 47(6):1231-8. PubMed ID: 7603465
[TBL] [Abstract][Full Text] [Related]
27. [Studies on herpes simplex virus thymidine kinase gene and GCV system for treatment of human bladder carcinoma].
He J; Chen Y; Li H; Lu Y; Yan Y; Tan X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Jun; 21(3):428-32. PubMed ID: 15250149
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.
Kokoris MS; Sabo P; Adman ET; Black ME
Gene Ther; 1999 Aug; 6(8):1415-26. PubMed ID: 10467366
[TBL] [Abstract][Full Text] [Related]
29. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.
Wildner O; Hoffmann D; Jogler C; Uberla K
Cancer Gene Ther; 2003 Oct; 10(10):791-802. PubMed ID: 14502232
[TBL] [Abstract][Full Text] [Related]
30. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir.
Howard BD; Boenicke L; Schniewind B; Henne-Bruns D; Kalthoff H
Cancer Gene Ther; 2000 Jun; 7(6):927-38. PubMed ID: 10880025
[TBL] [Abstract][Full Text] [Related]
31. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
[TBL] [Abstract][Full Text] [Related]
32. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
[TBL] [Abstract][Full Text] [Related]
33. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S
Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636
[TBL] [Abstract][Full Text] [Related]
34. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
35. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
36. N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors.
Hernandez AI; Familiar O; Negri A; Rodríguez-Barrios F; Gago F; Karlsson A; Camarasa MJ; Balzarini J; Pérez-Pérez MJ
J Med Chem; 2006 Dec; 49(26):7766-73. PubMed ID: 17181158
[TBL] [Abstract][Full Text] [Related]
37. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
39. Establishment of mutant murine mammary carcinoma FM3A cell strains transformed with the herpes simplex virus type 2 thymidine kinase gene.
Shimizu K; Ren L; Ayusawa D; Seno T; Balzarini J; De Clercq E
Cell Struct Funct; 1986 Sep; 11(3):295-301. PubMed ID: 3021345
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of ganciclovir toxicity in the herpes simplex virus thymidine kinase/ganciclovir administration system by ponicidin.
Hayashi K; Hayashi T; Sun HD; Takeda Y
Cancer Gene Ther; 2000 Jan; 7(1):45-52. PubMed ID: 10678355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
